Literature DB >> 1525828

Dominant negative MYC blocks transformation by ABL oncogenes.

C L Sawyers1, W Callahan, O N Witte.   

Abstract

A link between ABL oncogenes and MYC is suggested by the transformation synergy that is observed when MYC is expressed at high levels. Dominant negative MYC proteins were overexpressed in fibroblasts to determine if MYC complements ABL oncogene transformation or is essential for this process. Transformation by both v-abl and BCR-ABL oncogenes was reduced 5- to 10-fold, whereas transformation by the serine/threonine kinase oncogene v-mos was unaffected. Using a retrovirus construct modified to express BCR-ABL and MYC genes simultaneously, we show that dominant negative MYC suppressed transformation of primary mouse bone marrow pre-B cells by BCR-ABL. These observations demonstrate that c-MYC is essential for transformation and help define the pathway by which these proteins cause transformation.

Entities:  

Mesh:

Year:  1992        PMID: 1525828     DOI: 10.1016/0092-8674(92)90241-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  115 in total

1.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

2.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

3.  Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis.

Authors:  Mingming Zhao; Justyna A Janas; Masaru Niki; Pier Paolo Pandolfi; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

4.  c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors.

Authors:  Yinshi Guo; Chao Niu; Peter Breslin; Minghui Tang; Shubin Zhang; Wei Wei; Ameet R Kini; Gladell P Paner; Serhan Alkan; Stephan W Morris; Manuel Diaz; Patrick J Stiff; Jiwang Zhang
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

5.  Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.

Authors:  K Senechal; C Heaney; B Druker; C L Sawyers
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

6.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

7.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

8.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

9.  Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1.

Authors:  Jidong Zhu; John Blenis; Junying Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-01       Impact factor: 11.205

10.  IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Authors:  Mo-Ying Hsieh; Richard A Van Etten
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.